CubaseBio, a Stockholm startup, closed €5.9 million to commercialize a 3D spatial transcriptomics platform for organoids and intact tissues. Funding includes a €2M non‑dilutive EIC Transition grant and €3.9M in private financing led by Voima Ventures and Nordic Science Investments, with participation from Illumina Ventures and others. The founders cite DNA microscopy foundations from academic advisors Joshua Weinstein (UChicago) and Björn Högberg (Karolinska) and aim to enable transcriptome analysis in complex three‑dimensional samples that conventional 2D methods struggle to resolve. CubaseBio positions its tech for drug discovery and disease research where 3D spatial context matters. The raise underscores continued investor interest in spatial biology and technologies tailored to organoids and next‑generation preclinical models.